Homelife sciences

life sciences

Urica Therapeutics Expands Exclusive License Agreement with Fuji Yakuhin Co. Ltd. to Develop Dotinurad in Additional Territories Including Turkey and the Middle East and North Africa

Urica Therapeutics Expands Exclusive License Agreement with Fuji Yakuhin Co. Ltd. to Develop Dotinurad in Additional Territories Including Turkey and the Middle East and North Africa

December 14, 2022

Genprex Receives Safety Review Committee Approval to Proceed to Final Cohort in Acclaim-1 Phase 1 Dose Escalation Trial of REQORSA® in Combination with Tagrisso® in Advanced Non-Small Cell Lung Cancer

Genprex Receives Safety Review Committee Approval to Proceed to Final Cohort in Acclaim-1 Phase 1 Dose Escalation Trial of REQORSA® in Combination with Tagrisso® in Advanced Non-Small Cell Lung Cancer

December 14, 2022

Anavex Strengthens Scientific Advisory Board with Investigator from Phase 2b/3 Alzheimer’s Trial

Anavex Strengthens Scientific Advisory Board with Investigator from Phase 2b/3 Alzheimer’s Trial

December 14, 2022

Champions Oncology Reports Record Quarterly Revenue of $14.3 Million

Champions Oncology Reports Record Quarterly Revenue of $14.3 Million

December 13, 2022

Eiger Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before January 9, 2023 to Discuss Your Rights – EIGR

Eiger Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before January 9, 2023 to Discuss Your Rights – EIGR

December 13, 2022

Bears are Losing Control Over Galectin Therapeutics Inc. (GALT), Here’s Why It’s a ‘Buy’ Now

Bears are Losing Control Over Galectin Therapeutics Inc. (GALT), Here’s Why It’s a ‘Buy’ Now

December 13, 2022

Is Acer Therapeutics (ACER) Stock Outpacing Its Medical Peers This Year?

Is Acer Therapeutics (ACER) Stock Outpacing Its Medical Peers This Year?

December 13, 2022

ContraFect Announces Pricing of $7.0 Million Registered Direct Offering and Concurrent Private Placement

ContraFect Announces Pricing of $7.0 Million Registered Direct Offering and Concurrent Private Placement

December 13, 2022

Eyenovia Announces FDA Acceptance of New Drug Application for MydCombi(TM) for In-Office Pupil Dilation

Eyenovia Announces FDA Acceptance of New Drug Application for MydCombi(TM) for In-Office Pupil Dilation

December 13, 2022

Arbutus Completes Enrollment in its Phase 2a Clinical Trial Combining AB-729 with NA Therapy and Peginterferon alfa-2a in Patients with Chronic Hepatitis B Virus Infection

Arbutus Completes Enrollment in its Phase 2a Clinical Trial Combining AB-729 with NA Therapy and Peginterferon alfa-2a in Patients with Chronic Hepatitis B Virus Infection

December 13, 2022

« 1 … 11 12 13 14 15 … 557 »